2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Extended follow-up of KEYNOTE-240 shows pembrolizumab maintains OS, PFS in advanced HCC

Elaine Soliven, 20210312000000

Longer-term follow-up after the final analysis of the KEYNOTE-240* trial showed that improvements in overall survival (OS) and progression-free survival (PFS) with pembrolizumab were maintained in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, according to updated results of the trial presented at ASCO GI 2021.

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

Pearl Toh, 20210311150000

Adding bemarituzumab to mFOLFOX6 significantly improved survival outcomes and response rate compared with mFOLFOX6 alone in patients FGFR2b-positive, HER2-negative gastric cancer, according to the FIGHT study presented at the 2021 ASCO GI Cancer Symposium.

GI cancer patients could continue therapy during COVID-19 pandemic

Roshini Claire Anthony, 20210310180001

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

ATTRACTION-3: Nivolumab significantly improves OS in advanced ESCC

Elaine Soliven, 20210308000000

Treatment with nivolumab led to significantly improved overall survival (OS) in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to updated results of the ATTRACTION-3* study presented at ASCO GI 2021.

Anlotinib confers PFS, but not OS, benefit in metastatic CRC

Roshini Claire Anthony, 20210302180001

In patients with metastatic colorectal cancer (mCRC), the addition of anlotinib to best supportive care did not confer overall survival (OS) benefit, though there was improvement in progression-free survival (PFS), according to results of the phase III ALTER0703 trial presented at ASCO GI 2021.

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

Pearl Toh, 20210226140100

A combination therapy of S-1 plus docetaxel in the adjuvant setting is not only superior to S-1 alone for recurrence-free survival (RFS) following D2 gastrectomy for stage III gastric cancer, it also confers overall survival (OS) benefit, according to the updated analysis of the JACCRO GC-07 trial presented at ASCO GICS 2021.

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

Roshini Claire Anthony, 20210216180001

Infigratinib may be a suitable second- or later-line treatment option for patients with advanced or metastatic cholangiocarcinoma (CCA) with FGFR2* fusions or rearrangements, according to interim results of a phase II, open-label, single-arm study presented at ASCO GI 2021.

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

Audrey Abella, 20210202100000

In the final analysis of the phase III ClarIDHy trial, ivosidenib was well-tolerated and had a favourable overall survival (OS) benefit despite a high crossover rate from placebo among individuals with previously treated advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (mIDH1 CCA).

RAINBOW-Asia underlines benefit of ramucirumab-paclitaxel for stomach cancer

Audrey Abella, 20210201100000

The addition of the human immunoglobulin G1 monoclonal antibody ramucirumab to paclitaxel led to a significant progression-free survival (PFS) benefit in a subgroup of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed standard first-line chemotherapy with platinum and fluoropyrimidine (with or without anthracycline), according to the findings of the RAINBOW-Asia study, a bridging study of the RAINBOW trial, presented at ASCO GI 2021.